University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.

Cabaletta Bio, a US-based autoimmune disease treatment developer spun out of University of Pennsylvania, has completed a $74.8m initial public offering on the Nasdaq Global Select Market.
The spinout issued 6.8 million shares priced at $11 each, below its target range of $14 to $16. Its shares opened at $10 on the first day of trading last Friday and have so far remained below the IPO price.
Founded in 2017, Cabaletta Bio is focused on treatments for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in